Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 564

1.

Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.

Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK.

Cancer Immunol Immunother. 2009 Aug;58(8):1337-49. doi: 10.1007/s00262-009-0659-x. Epub 2009 Jan 24.

PMID:
19169682
2.

Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity.

Payton LA, Lewis JD, Byrne JA, Bright RK.

Cancer Immunol Immunother. 2008 Jun;57(6):799-811. Epub 2007 Oct 26.

PMID:
17962942
3.
5.

Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.

Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P.

Prostate. 2005 Feb 15;62(3):217-23.

PMID:
15389792
6.

Vaccine therapy of established tumors in the absence of autoimmunity.

Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.

Clin Cancer Res. 2003 May;9(5):1837-49.

7.

Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52.

Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, Yang L, Bright RK.

Mol Cancer Res. 2007 Feb;5(2):133-44.

8.
9.
10.

Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.

Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM.

Cancer Res. 2008 Feb 1;68(3):861-9. doi: 10.1158/0008-5472.CAN-07-0445.

11.

In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model, 4T1.

Gravekamp C, Leal B, Denny A, Bahar R, Lampkin S, Castro F, Kim SH, Moore D, Reddick R.

Cancer Immunol Immunother. 2008 Jul;57(7):1067-77.

PMID:
18094967
12.
13.

Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.

Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG.

Prostate. 2008 May 15;68(7):715-27. doi: 10.1002/pros.20689.

14.

A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF).

Lima J, Jenkins C, Guerrero A, Triozzi PL, Shaw DR, Strong TV.

Vaccine. 2005 Jan 26;23(10):1273-83.

PMID:
15652670
15.
16.

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.

Immunotherapy. 2011 Jun;3(6):735-46. doi: 10.2217/imt.11.59.

PMID:
21668311
17.

Versatile prostate cancer treatment with inducible caspase and interleukin-12.

Nikitina EY, Desai SA, Zhao X, Song W, Luo AZ, Gangula RD, Slawin KM, Spencer DM.

Cancer Res. 2005 May 15;65(10):4309-19.

18.
19.

Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor.

Wang XY, Li Y, Manjili MH, Repasky EA, Pardoll DM, Subjeck JR.

Cancer Immunol Immunother. 2002 Aug;51(6):311-9. Epub 2002 Jun 13.

PMID:
12111119
20.

A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy.

Schroten-Loef C, de Ridder CM, Reneman S, Crezee M, Dalgleish A, Todryk SM, Bangma CH, Kraaij R.

Cancer Immunol Immunother. 2009 Mar;58(3):373-81. doi: 10.1007/s00262-008-0560-z. Epub 2008 Jul 19.

PMID:
18641982

Supplemental Content

Support Center